Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Scynexis target lowered to $11 at RBC Capital Mkts — ’078 intravenous dose put on hold; not a show stopper but creates an overhang (3.27)RBC Capital Mkts lowers their SCYX tgt to $11 from $15. They have long made the case that the opportunity for SCY-078 could be maximized if both the oral form, which has cleared Phase 2 studies, and the i.v. form, which just completed Phase 1, are successfully developed. Based on our conversation with management, they think i.v. hurdle can be overcome, and regardless oral trials will continue, but shares could become range-bound near-term pending updates.<br/> <br/> SCYX -27% at seven month low premarket.</td> </tr></table>"